Abstract：
A 43-year-old man with pancytopenia was diagnosed with acute promyelocytic leukemia (APL). On the first day of induction therapy with all-trans retinoic acid (ATRA) alone, he presented with high fever and was found to have coronavirus disease 2019 (COVID-19) infection by SARS-CoV2 antigen test. While it is generally recommended to delay treatment for APL patients with COVID-19 unless urgent APL treatment is required, this patient needed to continue treatment due to APL-induced disseminated intravascular coagulation (DIC). Considering the challenge of distinguishing between differentiation syndrome (DS) and COVID-19 exacerbation, the ATRA dosage was reduced to 50%. The patient was able to continue treatment without development of DS or exacerbation of DIC, leading to his recovery from COVID-19 and remission of APL.
摘要：
一名43岁的全血细胞减少症患者被诊断为急性早幼粒细胞白血病（APL）。在单用全反式维甲酸（ATRA）诱导治疗的第一天，他表现为高烧，并通过SARS-CoV2抗原测试发现患有2019年冠状病毒病（COVID-19）感染。虽然通常建议推迟COVID-19的APL患者的治疗，除非需要紧急APL治疗，由于APL诱导的弥散性血管内凝血(DIC),该患者需要继续治疗.考虑到区分分化综合征（DS）和COVID-19加重的挑战，ATRA剂量减少至50%。患者能够继续治疗，没有发生DS或DIC恶化，导致他从COVID-19中康复并缓解APL。
